Table 1.
Demographic and clinical characteristics by ACS presentation
| Variables | STEMI | NSTEMI | UA | ANOVA |
| n = 321 | n = 358 | n = 520 | p-value | |
| Demographics | ||||
| Age | 60.8 +/- 12.5 | 63.2 +/- 13.0 * | 61.0 +/- 13.0 ‡ | p = 0.023 |
| Male | 70.7% | 56.7% * | 59.6% † | p < 0.001 |
| Caucasian | 85.3% | 81.6% | 76.5% † | p = 0.08 |
| Insured | 84.4% | 89.4% | 85.6% | p = 0.132 |
| Employed (full or part-time) | 46.3% | 36.9% * | 34.6% † | p = 0.02 |
| Past medical history | ||||
| History of myocardial infarction | 22.1% | 24.3% | 44.4% †‡ | p < 0.001 |
| History of percutaneous coronary intervention | 21.8% | 27.7% | 46.2% †‡ | p < 0.001 |
| History of coronary artery bypass graft | 10.0% | 18.4% * | 25% †‡ | p < 0.001 |
| Congestive heart failure | 3.7% | 7.8% * | 8.5% † | p = 0.027 |
| Hypertension | 56.4% | 63.4% | 72.7% †‡ | p < 0.001 |
| Diabetes mellitus | 19.6% | 24.6% | 32.7% †‡ | p < 0.001 |
| Hyperlipidemia | 51.1% | 58.1% | 68.3% †‡ | p < 0.001 |
| Transient ischemic attack | 1.2% | 1.7% | 2.1% | p = 0.65 |
| Cerebrovascular accident | 0.9% | 2.5% | 2.7% | p = 0.208 |
| Chronic obstructive pulmonary disease/asthma | 5.6% | 12.8% § | 12.9% † | p = 0.001 |
| Renal failure | 0.9% | 2.0% | 2.7% | p = 0.214 |
| Anemia | 62.2% | 61.7% | 50.2% | p < 0.001 |
| Tobacco use | 68.2% | 69.9% | 73.2% †‡ | p < 0.001 |
| Baseline health status | ||||
| SAQ angina rates | 95.0% | 87.4% * | 93.1% ‡ | p < 0.001 |
| SF-12 physical component scores | 42.7 +/- 11.4 | 39.1 +/- 12.3 * | 35.3 +/- 11.9 †‡ | p < 0.001 |
| SAQ quality of life scores | 50.4 +/- 17.3 | 53.4 +/- 20.2 * | 47.0 +/- 18.8 †‡ | p < 0.001 |
| ACS therapies | ||||
| Primary reperfusion | 86.3% | 65.1% * | 42% †‡ | p < 0.001 |
| Percutaneous coronary intervention | 63.9% | 62% § | 40.8% †‡ | p < 0.001 |
| Lysis | 22.4% | 3.1% § | 1.2% †‡ | p < 0.001 |
| Coronary artery bypass graft | 4.4% | 3.9% | 2.9% | p < 0.001 |
| Discharge meds | ||||
| Angiotensin converting enzyme inhibitors | 18.1% | 30.2% * | 36.5% †‡ | p < 0.001 |
| Lipid lowering | 79.8% | 77.7% | 75.2% | p = 0.191 |
| Beta-blockers | 87.5% | 84.4% | 72.5% †‡ | p < 0.001 |
| Calcium channel blockers | 10.0% | 14.2% | 23.7% †‡ | p < 0.001 |
| Nitrates | 9.3% | 12.0% | 18.1% †‡ | p < 0.001 |
| Acetylsalicylic acid (aspirin) | 95.9% | 93.9% | 92.7% | p = 0.379 |
*STEMI v NSTEMI p-value < 0.05; †STEMI v UA p-value < 0.05; ‡NSTEMI v UA p-value < 0.05; ANOVA, analysis of variance; NSTEMI, non-ST-elevation myocardial infarction; STEMI, ST-elevation myocardial infarction; UA, unstable angina; SAQ, Seattle Angina Questionnaire; SF-12, Short Form 12